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Abstract
Background Little information exists on the understand-
ing and management of painful diabetic peripheral neu-
ropathy (pDPN) between patients and healthcare
practitioners (HCPs).
Objective The objective of this study was to characterize
the patient perspective of pDPN and identify gaps in
patient and HCP perceptions of pDPN.
Methods An online survey of patients with type 1 or 2
diabetes mellitus who reported experiencing any symptoms
consistent with diabetic peripheral neuropathy (DPN) and
HCPs who treat diabetes was conducted in 2012 in the
USA. Patients were recruited via the Survey Sampling
national consumer research panel, and HCPs were recruited
from Epocrates’ national research panel. Survey questions
focused on the impact, understanding, and management of
pDPN, and interactions between patients and their HCPs.
Respondents who reported pain were re-contacted to obtain
further information on pain severity using a numerical
rating scale (0 = no pain, 10 = most pain).
Results Respondents included 1,004 patients (53 %
female, average age 55 years) and 500 HCPs (250 gener-
alists, 150 specialists, and 100 nurses/physician assistants).
While 83 % of patients reported pDPN symptoms, only
41 % of these patients had been diagnosed with DPN.
Eighty-five percent of those with pDPN reported that it
impacts daily activities. In contrast, HCPs estimated that of
their patients who experienced any type of DPN symptom,
41 % experienced pain and 38 % had daily activity limi-
tations because of their symptoms. Most HCPs (64 %)
never had their patients complete a DPN assessment
questionnaire, and only 41 % perform specific diagnostic
tests on all patients who report DPN symptoms. Patients
and HCPs both showed substantial clinical misperceptions
regarding the cause and management of pDPN; 53 % of
HCPs believed that adequate blood glucose control could
reverse DPN, and 43 % of pDPN patients were not sure if
DPN was reversible. There was also substantial discor-
dance between patients and HCPs regarding discussions of
DPN; only 49 % of pDPN patients reported that they speak
about symptoms at ‘‘every’’ or ‘‘most’’ appointments with
their HCP but 73 % of HCPs reported discussing DPN
symptoms at ‘‘every’’ or ‘‘most’’ visits.
Conclusions Not only do misperceptions exist on the
cause and management of pDPN among patients and
HCPs, but there are additional disparities between the
patient and HCP perspectives. These results suggests a
need for (1) educational initiatives on pDPN that target
patients and HCPs, and (2) initiating improved dialogue
between patients and their HCPs for discussing appropriate
management of pDPN that is distinct from treatment of the
underlying diabetes.
Electronic supplementary material The online version of this
article (doi:10.1007/s40271-013-0038-8) contains supplementary
material, which is available to authorized users.
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Key Points for Decision Makers
• Diabetic peripheral neuropathy and its painful
symptoms are under-recognized.
• Disparities exist between patient and healthcare pro-
vider perspectives of the impact and need for man-
agement of diabetic peripheral neuropathy and its
painful symptoms.
• Healthcare providers were characterized by sub-
stantial misperceptions regarding the cause and
management of diabetic peripheral neuropathy.
• These disparities and misperceptions may act as
barriers to appropriate patient management.
1 Background
Diabetes mellitus, with an estimated prevalence of 8.3 % in
the US population and 1.9 million new cases reported in
2010, is a health problem that continues to increase as a
result of both the aging of the population and unhealthy
lifestyles in a younger demographic [1]. Diabetic periph-
eral neuropathy (DPN) can be a late complication of type 1
and 2 diabetes that is caused by decreased microvascular
blood flow and lack of glycemic control and results in
irreversible nerve damage [2–4]. When DPN is accompa-
nied by painful symptoms it is known as painful diabetic
peripheral neuropathy (pDPN). The painful symptoms
generally manifest as sensations typically described by
patients with neuropathic pain and may include the quali-
tative pain descriptors of burning, tingling, electric, sharp,
shooting, and lancinating [5]. Estimates suggest that the
overall prevalence of pDPN in the diabetic population is
15 % [6]. Since there is no cure for pDPN, management
strategies have included slowing progression through
maintenance of glycemic control, and symptomatic thera-
pies, especially those targeting pain [7].
The substantial disease burden associated with pDPN
has been well-documented. This burden is related to the
reductions in function, quality of life, and productivity
experienced by patients, as well as to greater use of
healthcare resources that results in higher costs relative to
both the general population and patients with diabetes who
do not have pDPN [8–13].
Despite the numerous studies evaluating quality of life
and other patient-reported outcomes in pDPN, no published
studies have characterized patient knowledge and percep-
tions of pDPN, although patients with pDPN were included
in a patient-level survey of attitudes and barriers to treat-
ment of neuropathic pain [14]. Furthermore, there is little
information on gaps in the dialogue between patients and
their healthcare practitioners (HCPs). Such gaps may be of
clinical relevance with respect to appropriate management
strategies, since a previous study suggested some disparity
between the perspectives of patients and their HCPs,
especially with regard to rating pDPN severity [13, 15].
Therefore, a survey was conducted among patients with
pDPN and among HCPs who treat diabetes to characterize
their perceptions and identify any knowledge gaps or dis-
parities that may be targeted for educational initiatives.
2 Methods
Versta Research (Evanston, IL, USA) conducted an online
survey in the USA from 8 May through 16 May 2012 in
collaboration with the American Chronic Pain Association.
Adult patients (C18 years of age) diagnosed with type 1 or
2 diabetes were recruited via the Survey Sampling national
consumer research panel. For inclusion, patients were
screened based on self-report of experiencing any symp-
toms consistent with DPN in the feet, hands, legs, or arms.
These symptoms included sensations of burning or feeling
of heat; electric shock-like feelings; extreme sensitivity to
touch, even light touch; numbness, tingling, or inability to
feel things; prickling or pins and needles; shooting pain or
sharp jabbing; and stinging or throbbing.
HCPs were recruited from Epocrates’ national research
panel. Since the patient and HCP populations were inde-
pendent, the HCPs were not necessarily providing care to
the patient survey participants.
While the HCP survey focused on understanding the
impact, cause, and management of DPN symptoms, both
surveys (Electronic Supplementary Material Online
Resources 1 and 2) included questions on DPN symptoms
as well as specific questions on painful symptoms of DPN.
Both surveys also included questions on interactions
between patients and HCPs. Survey results reflect an
unweighted population.
A subpopulation of patients who reported the presence
of DPN pain (i.e., pDPN) was re-contacted in order to
obtain additional information on pain severity. The pain
severity was assessed using a 0–10 numerical rating scale,
where 0 = no pain and 10 = the most pain, based on the
question ‘‘How would you rate your pain on average when
left untreated? That is, how would you rate your pain
symptoms prior to taking any medication or pain remedy?’’
Pain severity was considered mild, moderate, and severe
based on scores of 1–3, 4–6, and 7–10, respectively, which
have previously been shown to correlate with these severity
levels in patients with pDPN [16].
All statistical analyses were performed to evaluate sig-
nificance at the 95 % level using SPSS (IBM, Armonk,
NY) and WinCross (The Analytical Group, Inc., Scottsdale,
AZ). Bivariate data were analyzed using independent t tests
for means and independent z tests for percentages.
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3 Results
3.1 Respondent Populations
The patient population consisted of 1,004 adults in the
USA diagnosed with type 1 or type 2 diabetes who self-
reported symptoms consistent with DPN. The mean age
was 55 years, there were slightly more women than men
(53 vs. 47 %), and the mean time since diabetes diagnosis
was 12 years. There was similar representation among the
North (26.1 %), East (20.2 %), South (23.3 %), and West
(30.4 %) regions of the USA, and, of note, the results
presented below were generally similar among the four
geographic regions.
The HCP survey encompassed a cross-section of 500
clinicians who treat patients with diabetes and consisted of
50 % generalist physicians (family practice, general prac-
tice, and internists), 30 % specialist physicians (endocri-
nologists, neurologists, pain medicine specialists, and
podiatrists), and 20 % nurses/physicians assistants. Over-
all, 63 % of the HCPs reported that they saw[50 diabetes
patients per month and 28 % saw between 21 and 50 per
month. The patient and physician populations were derived
independently, and thus the HCPs were not necessarily
providing care to the patient survey participants.
3.2 Painful Symptoms and their Impact
In the total population, 83 % (832 of 1,004) reported
experiencing painful DPN symptoms, but only 41 % of
these (n = 343 of 832) were diagnosed with DPN. Most of
the patients who experienced pain (81 %) stated that this
pain was different from other kinds of pain they were used
to feeling, and they reported a wide range of sensory
symptoms typical of neuropathic pain (Table 1). The most
frequent of these symptoms was ‘‘numbness and tingling,’’
which was reported by 80 % of the symptomatic patients.
DPN symptoms were reported as being experienced
‘‘most’’ or ‘‘all of the time’’ by 50 % of the symptomatic
patients, and 28 % of the symptomatic patients said that
their symptoms were always painful.
Of the 832 patients who experienced painful symptoms
of DPN (pDPN) and were re-contacted to obtain further
information on pain severity, 393 responded (52 % female,
average age 56 years); approximately half (49 %) reported
severe pain, and 13 % and 38 % reported mild or moderate
pain, respectively. Among those for whom pain severity
data were available, greater proportions of patients reported
the sensory symptoms at increasing levels of pain, and
these proportions were significant for severe pain relative
to mild and moderate pain across symptoms (P \ 0.05)
(Table 1). Among the patients with severe pain, 67 %
reported experiencing symptoms ‘‘all’’ or ‘‘most of the
time’’ compared with 18 % of those with mild pain and
38 % of those with moderate pain (both P \ 0.05). Addi-
tionally, a significantly greater proportion of patients with
severe pain reported DPN symptoms as always being
painful (47 %) than in those with mild (10 %) and mod-
erate pain (11 %) (P \ 0.05 for both comparisons).
Overall, substantial proportions of patients reported that
DPN impacts their daily function ‘‘a lot’’ or ‘‘somewhat’’
(Fig. 1). For all activities except for work, patients more
frequently reported ‘‘somewhat’’ rather than ‘‘a lot’’ of
impact, whereas the impact on work was more frequently
reported as ‘‘a lot.’’ The most frequently affected function
was sleep (61 %), followed by exercise (57 %) and the
ability to walk (56 %). In the re-contacted subpopulation, the
impact of pain was significantly greater at higher pain
severity levels in all function categories (P B 0.05) (Fig. 2).
3.3 Patient–Physician Disparities
Despite the substantial presence of painful symptoms and
their impact on daily activity reported by patients, there
was considerable disparity between patient and HCP per-
spectives (Fig. 3). As shown in Fig. 3a, 83 % of patients
reported that their symptoms are painful, but HCPs
underestimated this prevalence by approximately 50 %;
Table 1 Type and prevalence of sensory symptoms among patients who reported pain associated with diabetic peripheral neuropathy
Sensory symptom Patients experiencing
painful symptoms
(%) (n = 832)
Patients reporting pain severity (%) (n = 393)
Mild Moderate Severe
Numbness and tingling 80 62 79* 87*,
Prickling or pins and needles 72 60 68 79*,
Shooting pain or sharp jabbing 59 30 53* 76*,
Burning or feelings of heat 53 28 46* 60*,
Stinging or throbbing 52 28 47* 69*,
Electric shock-like feelings 49 32 42 63*,
Extreme sensitivity to even light touches 36 18 24 41*,
* P \ 0.05 versus mild;  P \ 0.05 versus moderate
Painful Diabetic Peripheral Neuropathy Survey 109
HCPs estimated that only 41 % of their DPN patients
experienced pain. Similarly, while daily activities were
reported to be affected by DPN symptoms by 77 % of the
patients, HCPs estimated that only 38 % of patients had
their daily activities affected by DPN symptoms (Fig. 3a).
Furthermore, these perceptual disparities regarding the
presence and importance of DPN symptoms were high-
lighted by the report that 64 % of HCPs never have their
patients complete a DPN assessment questionnaire, and
that only 41 % perform specific diagnostic tests on all
patients who report DPN symptoms. There was also dis-
cordance between patients and HCPs regarding the level of
detail in which DPN symptoms were discussed (Fig. 3b);
while most pDPN patients felt that their symptoms were
discussed only briefly or in passing, more HCPs than
patients, 45 and 28 %, respectively, felt that DPN symp-
toms were discussed in detail. These differences in per-
ception between patients and HCPs were consistent for all
specific issues related to diabetes and DPN that were
queried (Table 2). Although issues related to diabetes, such
as glycemic control and diabetes-related medications, were
reported to be frequently discussed by both patients and
HCPs, there was a large disparity in the perception of how
frequently diabetes sequelae were discussed, especially
related to pDPN such as nerve damage, for which 61 % of
HCPs reported discussing this issue with their patients at
‘‘every’’ or ‘‘most visits,’’ but only 39 % of pDPN patients
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Fig. 1 Patient-reported impact
of diabetic peripheral
























































*P ≤ 0.05 versus mild; †P ≤ 0.05 versus mild and moderate 
Fig. 2 Relationship between
pain severity and impact of
painful diabetic peripheral
neuropathy on daily function
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Although patient discussion of DPN symptoms with
their physician was reported more often with increasing
levels of pain severity, the proportions of patients dis-
cussing their symptoms was low. Only 13 and 24 % of
patients with mild and moderate pain, respectively, spoke
in detail about their symptoms, and even among patients
with severe pain, less than one-third (32 %) of patients
discussed their symptoms in detail with their physician
(P \ 0.05 vs. mild and moderate pain).
There was general agreement regarding the role of HCPs
in symptom management: 95 % of pDPN patients and
97 % of HCPs endorsed HCP responsibility for helping
patients manage their symptoms. However, there were still
several gaps in the avenues of communication between the
two groups, manifested by the perceived roles that each
population played in raising and discussing symptoms and
their management. Patients reported that they raised issues
relating to their symptoms on average 57 % of the time,
and 49 % of pDPN patients stated that HCPs tend to dis-
cuss things only when asked. In contrast, HCPs felt that it
was them who raised the issues 59 % of the time on
average, and 70 % stated that they usually asked patients
about DPN symptoms even if a patient did not talk about it.
Several barriers to adequate communication were identified
by pDPN patients, including that it was difficult for them to
describe their symptoms (56 %), that they were reluctant to
talk about their symptoms with their HCPs (37 %), and that
their symptoms may have reflected poorly on how well
they managed their diabetes (59 %).
Several key clinical misperceptions were identified as
being common, including that substantial proportions of
patients and HCPs had an unclear understanding of the
relationship between blood glucose and DPN symptom
management. Among pDPN patients, more than half
(51 %) stated they believed that controlling blood sugar
would help DPN symptoms go away, and 31 % were
unsure. Almost one patient out of five (18 %) also believed
that nerve damage from DPN was reversible, while 43 %
were unsure. Similar misperceptions were observed among
HCPs; 53 % believed that patients could reverse DPN with
adequate blood glucose control, and 76 % believed that













































Fig. 3 Disparities between patient and healthcare practitioner per-
spectives. a Diabetic peripheral neuropathy symptoms and their
impact (patient n = 1,004; healthcare practitioner n = 500). b Dis-
cussion of symptoms of diabetic peripheral neuropathy; proportions
reflect painful diabetic peripheral neuropathy patients who discussed
their symptoms with their physician (n = 724), and all healthcare
practitioners (n = 500). HCPs healthcare practitioners
Table 2 Proportion of respondents reporting diabetes mellitus issues







Blood sugar (glucose) levels 82 93
Medications for your diabetes 71 84
Eating habits and diet 53 82
Heart, lungs, and potential cardiovascular
problems including high blood pressure
53 74
Exercise and lifestyle 49 83
The symptoms in your feet, hands, arms,
or legs that you described earlier
46 73
Foot-related issues 42 68
How the symptoms in your feet, hands,
arms, or legs interfere with daily
activities
38 60
Potential nerve damage 36 61
Kidney function and the potential for
problems
38 57
Eye and potential vision problems 36 60
The emotional toll of having diabetes 24 29
HCPs healthcare practitioners
Painful Diabetic Peripheral Neuropathy Survey 111
Both populations acknowledged the value of learning
more about DPN: at least half of DPN patients and HCPs
expressed a desire for obtaining additional information on
particular issues that could help them understand and treat
this condition (Table 3). Educational topics included the
relationship between diabetes and DPN, and the causes and
manifestations of pDPN that distinguish it from other types
of pain. Additionally, the majority of HCPs expressed a
desire for more information specifically related to manag-
ing DPN-related pain, including non-pharmacologic strat-
egies (87 %) and which medications have been approved
by the US FDA to treat DPN pain (63 %).
4 Discussion
This survey, the first to characterize perceptions of DPN
from the perspectives of patients and HCPs, highlights the
existence of communication gaps between these two pop-
ulations and identifies clinically relevant misperceptions
regarding this condition. While these gaps and misper-
ceptions likely act as barriers to disease management, their
identification can also be used to inform the development
of appropriate educational initiatives to promote better
communication between patients and HCPs and a better
understanding of DPN and its painful symptoms.
Since recognition of pDPN is essential to its treatment, it
is especially relevant to note that HCPs underestimated the
magnitude of patient-reported painful symptoms with
respect to their prevalence and their impact on daily
function. Both of these outcomes were reported by more
than twice as many patients than was estimated by HCPs.
This disparity may not necessarily be surprising given that
a previous study also reported the presence of substantial
discordance between patients and physicians with regard to
rating pDPN severity, including underestimation of sever-
ity in almost half (46.7 %) of the patients who reported
severe pDPN [15]. Such discordance, especially with
regard to patient-reported prevalence of symptoms, is
likely to affect timely initiation of therapy and, ultimately,
long-term outcomes. Although the proportion of patients
who were being treated for pDPN was not captured in the
current analysis, a cross-sectional study of patients with
diabetes and pDPN by Daousi et al. [17] reported that 39 %
of patients had never received treatment for their painful
symptoms.
Based on the present survey, it may be proposed that the
observed disparities between patients and HCPs may be
due, at least in part, to less than optimal communication
between patients and clinicians. This proposal is also
supported by Daousi et al. [17], where nearly 13 % of
patients never reported their symptoms to their treating
physician. Furthermore, reports of the lack of use of
assessment questionnaires and diagnostic tests by a sub-
stantial proportion of HCPs in the current study may also
be a contributing factor to the low HCP estimates, since
such assessments would enable identification of the pre-
sence of pDPN even among patients who may be reluctant
to discuss their pain because of perceptions of embarrass-
ment regarding their diabetes management.
The types of sensory symptoms and frequency of pain
reported by patients were consistent with a survey char-
acterizing the nature and scope of the painful symptoms
[5]. However, the proportion of patients with severe pain
(49.4 %) was almost twice as high as that reported in two
previous patient-level studies (*25 %) [9, 18], although it
was similar to that of a different study (51 %) [19]. These
differences may be a reflection of the sampled populations
as well as the specific question used to elicit pain severity
levels.
There appeared to be a significant association between
pain severity and impact on daily function. Such a rela-
tionship of greater levels of pain severity with decreased
function, as well as with poorer outcomes on other patient-
reported measures, have been documented in several
studies of pDPN [9, 18–20]. In this regard, it should also be
noted that treatment-related reductions in DPN pain con-
sequently result in improved functional outcomes [21].
However, despite this association between pain severity
and function, relatively few patients, even those with
severe pain, discussed their symptoms in detail with their
physician.
Limited knowledge on the cause and treatment of pDPN
may be expected among a proportion of patients. However,
it was somewhat surprising to observe the rate with which
HCPs demonstrated a poor understanding of the relation-
ship between pDPN and diabetes, including a lack of
knowledge of the irreversibility of DPN-associated nerve
damage. While such misunderstandings on the part of
HCPs have not previously been documented, it may
Table 3 Request for more learning regarding diabetic peripheral
neuropathy






The link between diabetes mellitus
and DPN
51 50
Cause of DPN 54 64
Difference between nerve pain and
other types of pain
58 60
How DPN causes pain or numbness 58 64
When to see a doctor about DPN 49 –
DPN diabetic peripheral neuropathy, HCPs healthcare practitioners
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partially account for reports that pDPN is under- or sub-
optimally treated, and that satisfaction with treatment is
low among patients [22, 23].
Importantly, the identification of these misperceptions,
and the willingness by patients and HCPs to obtain more
information provides a focus for developing educational
initiatives that promote greater understanding of pDPN and
its treatment.
4.1 Limitations
As with any survey dependent upon respondents, an
important limitation is potential selection bias, since
patients and HCPs who agreed to participate may have
characteristics and perceptions different from those who
refused. A similar limitation is that the patient-level data on
pain and symptoms were based on self-report, and as such
may be subject to recall bias and human error. It should
also be noted that this study did not capture other outcomes
that may have contributed to patients’ perceptions of the
pain experience, such as mood, negative emotions and
thoughts, poor pain control, or poor past interactions with
HCPs. Nevertheless, these factors could be a potential
source of sampling or recall bias contributing to the high
proportion of patients reporting painful symptoms.
An additional limitation that was previous acknowl-
edged is that the two samples were obtained independently
(the patients surveyed were unlikely to be patients of the
HCPs surveyed), and therefore were not necessarily rela-
ted. It is therefore possible that if patients were surveyed
together with their HCPs, the results might have been
different with regard to the observed levels of disparity.
The generalizability of these results to the clinical setting
may also be limited; although the demographic and clinical
characteristics were generally consistent with other US
surveys that relied on web-based or clinical practice pop-
ulations [13, 19, 23], the data reflect an unweighted pop-
ulation. However, an observed similarity of results across
geographic regions suggests the robustness of the survey.
5 Conclusions
There was notable discordance between patients’ and
HCPs’ perspectives not only on the presence and impact of
pDPN symptoms, but also on how often these are discussed
during clinical visits. While misperceptions regarding the
cause and management of pDPN were common among
patients and HCPs, both populations expressed a desire to
learn more about its cause and appropriate management.
These results suggest a need for educational initiatives on
pDPN that target patients and their HCPs.
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